How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2021 Feb 2

PMID 33526567

Citations 8

Authors

Mara Cruellas

Alfonso Yubero

Maria Zapata

Eva M Galvez

Marta Gascon

Dolores Isla

Rodrigo Lastra

Luis Martinez-Lostao

Maitane Ocariz

Julian Pardo

Ariel Ramirez

Andrea Sesma

Irene Torres-Ramon

Jose Ramon Pano

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has become a new paradigm in oncology, improving outcomes for several types of cancer. However, there are some aspects about its management that remain uncertain. One of the key points that needs better understanding is the interaction between immunotherapy and gut microbiome and how modulation of the microbiome might modify the efficacy of immunotherapy. Consequently, the negative impact of systemic antibiotics and corticosteroids on the efficacy of immunotherapy needs to be clarified.

Citing Articles

Long COVID and gut candidiasis: What is the existing relationship?.

Bistagnino F, Pizzi D, Mantovani F, Antonino J, Tovani-Palone M World J Gastroenterol. 2024; 30(37):4104-4114.

PMID: 39474404 PMC: 11514539. DOI: 10.3748/wjg.v30.i37.4104.

Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer.

Zapata-Garcia M, Moratiel-Pellitero A, Isla D, Galvez E, Gascon-Ruiz M, Sesma A Heliyon. 2024; 10(13):e33684.

PMID: 39050456 PMC: 11268177. DOI: 10.1016/j.heliyon.2024.e33684.

The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.

Duttagupta S, Hakozaki T, Routy B, Messaoudene M Curr Oncol. 2023; 30(11):9406-9427.

PMID: 37999101 PMC: 10669980. DOI: 10.3390/curroncol30110681.

Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.

Nelli F, Virtuoso A, Giannarelli D, Fabbri A, Giron Berrios J, Marrucci E Curr Oncol. 2023; 30(9):8117-8133.

PMID: 37754504 PMC: 10527930. DOI: 10.3390/curroncol30090589.

Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.

Nelli F, Virtuoso A, Giron Berrios J, Giannarelli D, Fabbri A, Marrucci E Cancer Chemother Pharmacol. 2022; 89(4):529-537.

PMID: 35301584 DOI: 10.1007/s00280-022-04416-4.

References

Abdelhamid A, El-Masry S, El-Dougdoug N . Probiotic and strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. EPMA J. 2019; 10(4):337-350. PMC: 6883010. DOI: 10.1007/s13167-019-00184-z. View

Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J . Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019; 8(4):e1568812. PMC: 6422373. DOI: 10.1080/2162402X.2019.1568812. View

Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17):1714-1768. PMC: 6481621. DOI: 10.1200/JCO.2017.77.6385. View

Farmakiotis D . The Human Microbiome and Checkpoint Inhibition: Potential Benefits From Antibiotic Stewardship. Clin Infect Dis. 2019; 71(3):701-702. DOI: 10.1093/cid/ciz1003. View

Chalabi M, Cardona A, Nagarkar D, Dhawahir Scala A, Gandara D, Rittmeyer A . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020; 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. View

Gorska A, Przystupski D, Niemczura M, Kulbacka J . Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy. Curr Microbiol. 2019; 76(8):939-949. PMC: 6586914. DOI: 10.1007/s00284-019-01679-8. View

Indini A, Rijavec E, Grossi F . Immune related adverse events and response to immunotherapy: Focus on corticosteroids. Lung Cancer. 2020; 145:225. DOI: 10.1016/j.lungcan.2020.02.009. View

Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M . Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019; 132:72-78. DOI: 10.1016/j.lungcan.2019.04.008. View

Kaderbhai C, Richard C, Fumet J, Aarnink A, Foucher P, Coudert B . Antibiotic Use Does Not Appear to Influence Response to Nivolumab. Anticancer Res. 2017; 37(6):3195-3200. DOI: 10.21873/anticanres.11680. View

10.

Hakozaki T, Okuma Y, Omori M, Hosomi Y . Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett. 2019; 17(3):2946-2952. PMC: 6365976. DOI: 10.3892/ol.2019.9899. View

11.

Huang E, Inoue T, Leone V, Dalal S, Touw K, Wang Y . Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2015; 21(5):963-72. PMC: 4402247. DOI: 10.1097/MIB.0000000000000332. View

12.

Della Corte C, Morgillo F . Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open. 2019; 4(1):e000477. PMC: 6435247. DOI: 10.1136/esmoopen-2018-000477. View

13.

Kuczma M, Ding Z, Li T, Habtetsion T, Chen T, Hao Z . The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget. 2018; 8(67):111931-111942. PMC: 5762370. DOI: 10.18632/oncotarget.22953. View

14.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski T . The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018; 359(6382):1366-1370. DOI: 10.1126/science.aar6918. View

15.

Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H . Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018; 29(6):1437-1444. PMC: 6354674. DOI: 10.1093/annonc/mdy103. View

16.

Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G . NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2020; 15(7):1147-1159. DOI: 10.1016/j.jtho.2020.03.002. View

17.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019; 5(10):1411-1420. PMC: 6659167. DOI: 10.1001/jamaoncol.2019.2187. View

18.

Johnson D, Chandra S, Sosman J . Immune Checkpoint Inhibitor Toxicity in 2018. JAMA. 2018; 320(16):1702-1703. DOI: 10.1001/jama.2018.13995. View

19.

Arbour K, Mezquita L, Long N, Rizvi H, Auclin E, Ni A . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(28):2872-2878. DOI: 10.1200/JCO.2018.79.0006. View

20.

Dubin K, Callahan M, Ren B, Khanin R, Viale A, Ling L . Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016; 7:10391. PMC: 4740747. DOI: 10.1038/ncomms10391. View